|
|
|
|
|
06.08.26 - 22:06
|
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results (Business Wire)
|
|
|
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026.
Recent Business Highlights
Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approximately $13 million from insiders and the remaining $33.8 million in net proceeds from outside investors. Subsequent to the close of Q2, the Company raised an additional $10.7 million in net proceeds through the ATM and $1.8 million in gross proceeds from the exercise of warrants.
Endocardial Catheter AF Ablation
Surpassed the halfway point of enrollment in NANOPULSE-AF, exceeding 82 evaluable patients, the U.S. IDE pivotal clinical study of the nPulse Cardiac Catheter System. The Company reiterates its enrollment...
|
|
|
21.07.26 - 22:06
|
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026 (Business Wire)
|
|
|
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 3486060. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/.About Pulse Biosciences®Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company's proprietary nPulse...
|
|
|
15.07.26 - 22:09
|
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).Pulse has awarded inducement options to three new employees to purchase, in aggregate, up to 9,000 shares of Company common stock. The Company's independent Compensation Committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $25.89 per share, which is equal to the closing price of the Company's common stock on July 13, 2026, and all ...
|
|
|
|
|
10.06.26 - 13:03
|
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire)
|
|
|
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the “200% Warrants”), which were issued in the Company's 2024 rights offering (the “Rights Offering”), pursuant to the Company's Registration Statement on Form S-3, as amended (File No. 333-278494), may be exercised by the holders thereof until 5:00 p.m., Eastern time, on July 13, 2026, at the exercise price of $11.00 per share of Company common stock, $0.001 par value per share. Any 200% Warrants not exercised before 5:00 p.m., Eastern time, on July 13, 2026 (the “Redemption Date”), will be redeemed by the Company for $0.01 per 200% Warrant share...
|
|
|
|
|
|
|
|
|
|
|
12.05.26 - 13:06
|
ATM Equity Purchases by Pulse Biosciences′ Co-Chairmen Total Approximately $13.3 Million (Business Wire)
|
|
|
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window.
In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences' common stock for an aggregate purchase price of approximately $13.3 million.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company's proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Compan...
|
|
|
|
|
|
|
|
|
06.05.26 - 14:06
|
Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase (Business Wire)
|
|
|
ROCHESTER, N.Y.--(BUSINESS WIRE)--Turbett Surgical is proud to announce the appointment of Kevin Danahy as President and Chief Executive Officer. A visionary leader known for his "founder-mentality," Danahy joins the company with a mandate to instill a high-performance culture and lead the organization through its next era of clinical expansion and commercial excellence.
Danahy most recently served at Pulse Biosciences in key executive roles, including President and CEO, during the company's critical stage of transition to a cardiac and oncology focus. Previously, he was President and CEO of private equity-backed Solmetex, where he successfully rebuilt the executive leadership team and accelerated the company to a successful exit. In addition to his leadership success at both Pulse and Solmetex, Kevin developed the foundation of his leadership skills over two decades of leadership positions at several of the world's most respected medical device companies, including Zimmer Biomet, Intuitive Su...
|
|
|
|
|
|
|
|
|
04.05.26 - 13:06
|
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results (Business Wire)
|
|
|
Accelerates Enrollment Timeline for the Cardiac Catheter IDE
Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial ResultsHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026.
Recent Business Highlights
Endocardial Catheter AF Ablation
Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonstrating exceptional procedure efficiency and durable outcomes.
Presented late-breaking data at Heart Rhythm 2026. The expanded data set included increased evaluable patient counts from the first-in-human European feasibility study showing sustained 100% procedural success by Holter monitor at 6 months (95/95 evaluable patients), 96% procedural success by Holt...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
